FR3120311B1 - Préparation extemporanée et procédé cosmétique de lissage des cheveux utilisant cette préparation - Google Patents

Préparation extemporanée et procédé cosmétique de lissage des cheveux utilisant cette préparation Download PDF

Info

Publication number
FR3120311B1
FR3120311B1 FR2102096A FR2102096A FR3120311B1 FR 3120311 B1 FR3120311 B1 FR 3120311B1 FR 2102096 A FR2102096 A FR 2102096A FR 2102096 A FR2102096 A FR 2102096A FR 3120311 B1 FR3120311 B1 FR 3120311B1
Authority
FR
France
Prior art keywords
preparation
cosmetic process
straightening hair
extemporaneous
extemporaneous preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2102096A
Other languages
English (en)
Other versions
FR3120311A1 (fr
Inventor
Fatima Errakhaoui-Mura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FATIMA ERRAKHAOUI MURA, FR
Original Assignee
Novantic Cosmetics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novantic Cosmetics filed Critical Novantic Cosmetics
Priority to FR2102096A priority Critical patent/FR3120311B1/fr
Priority to PCT/FR2022/050389 priority patent/WO2022185019A1/fr
Priority to EP22712965.7A priority patent/EP4301319A1/fr
Priority to US18/548,234 priority patent/US20240139093A1/en
Publication of FR3120311A1 publication Critical patent/FR3120311A1/fr
Application granted granted Critical
Publication of FR3120311B1 publication Critical patent/FR3120311B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/04—Preparations for permanent waving or straightening the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une préparation extemporanée, comprenant, dans un support aqueux physiologiquement acceptable, un extrait de galles de Tamaris se présentant sous la forme de grains de galle broyés et de la poudre d’oxyde de cuivre. Elle porte également sur un procédé cosmétique de lissage des cheveux utilisant cette préparation.
FR2102096A 2021-03-04 2021-03-04 Préparation extemporanée et procédé cosmétique de lissage des cheveux utilisant cette préparation Active FR3120311B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR2102096A FR3120311B1 (fr) 2021-03-04 2021-03-04 Préparation extemporanée et procédé cosmétique de lissage des cheveux utilisant cette préparation
PCT/FR2022/050389 WO2022185019A1 (fr) 2021-03-04 2022-03-04 Préparation extemporanée et procédé cosmétique de lissage des cheveux utilisant cette préparation
EP22712965.7A EP4301319A1 (fr) 2021-03-04 2022-03-04 Préparation extemporanée et procédé cosmétique de lissage des cheveux utilisant cette préparation
US18/548,234 US20240139093A1 (en) 2021-03-04 2022-03-04 Extemporaneous preparation and cosmetic method for straightening hair using said preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2102096A FR3120311B1 (fr) 2021-03-04 2021-03-04 Préparation extemporanée et procédé cosmétique de lissage des cheveux utilisant cette préparation
FR2102096 2021-03-04

Publications (2)

Publication Number Publication Date
FR3120311A1 FR3120311A1 (fr) 2022-09-09
FR3120311B1 true FR3120311B1 (fr) 2024-04-12

Family

ID=75539571

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2102096A Active FR3120311B1 (fr) 2021-03-04 2021-03-04 Préparation extemporanée et procédé cosmétique de lissage des cheveux utilisant cette préparation

Country Status (4)

Country Link
US (1) US20240139093A1 (fr)
EP (1) EP4301319A1 (fr)
FR (1) FR3120311B1 (fr)
WO (1) WO2022185019A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA21838A1 (fr) * 1990-05-10 1990-12-31 Maria Zaari Procede pour le traitement des cheveux a base de plantes et produits naturels contre la chute des cheveux ainsi que leur repousse et leur beaute .
FR2672491A1 (fr) 1991-02-07 1992-08-14 David Zaboub Louisa Produit pour cheveux a base de produits naturels servant a raidir, teinter et embellir.
US20030185785A1 (en) 2002-03-29 2003-10-02 Daniel Moyal Composition for hair straightening and method for its preparation
US20090163449A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives
MX371226B (es) * 2015-07-22 2020-01-09 Landa Labs 2012 Ltd Composiciones de proteccion ultravioleta.
JP7135862B2 (ja) * 2016-11-07 2022-09-13 日清紡ホールディングス株式会社 皮膚化粧料

Also Published As

Publication number Publication date
US20240139093A1 (en) 2024-05-02
EP4301319A1 (fr) 2024-01-10
FR3120311A1 (fr) 2022-09-09
WO2022185019A1 (fr) 2022-09-09

Similar Documents

Publication Publication Date Title
Facchinetti et al. Facts and new hopes on selective FGFR inhibitors in solid tumors
Gerosa et al. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions
Cao et al. Targeting of hematologic malignancies with PTC299, a novel potent inhibitor of dihydroorotate dehydrogenase with favorable pharmaceutical properties
Reck et al. Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in patients with extensive-disease small cell lung cancer
Jabbour et al. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Aoki et al. A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency
Tu et al. Afatinib exerts immunomodulatory effects by targeting the pyrimidine biosynthesis enzyme CAD
Tian et al. CYP3A4-mediated pharmacokinetic interactions in cancer therapy
TW200510306A (en) Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
PH12014501001B1 (en) Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
Parzych et al. Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97
WO2019090205A1 (fr) Compositions d'inhibiteur de kinase pim, procédés et utilisations de celles-ci
FR3120311B1 (fr) Préparation extemporanée et procédé cosmétique de lissage des cheveux utilisant cette préparation
WO2011070444A2 (fr) Compositions et procédés pour traiter l'ataxie de friedreich
Gemma et al. Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure–activity relationship studies
JP2024500754A (ja) 早期特発性パーキンソン病のための治療レジメン
Cordes et al. Statins limit coenzyme Q synthesis and metabolically synergize with MEK inhibition in pancreatic tumors
Giansanti et al. Evaluating the promiscuous nature of tyrosine kinase inhibitors assessed in A431 epidermoid carcinoma cells by both chemical-and phosphoproteomics
WO2020236502A1 (fr) Polythérapies pour le traitement du cancer
Katoulis et al. Baricitinib in alopecia areata: Real‐world data from a case series in Greece.
Nguyen et al. Synergistic effects of type I PRMT1 and type II PRMT5 inhibitors against multiple myeloma
WO2021076703A1 (fr) Composés et procédés de modulation de protéines immunitaires
Xu et al. Patient-reported quality of life in Asian patients with ER+/HER2− advanced breast cancer treated with palbociclib plus letrozole in the PALOMA-4 trial
Trujillo et al. Abemaciclib plus fulvestrant in participants with HR+/HER2-advanced breast cancer: A pooled analysis of the endocrine therapy naïve (EN) participants in MONARCH 2

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220909

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

TP Transmission of property

Owner name: FATIMA ERRAKHAOUI MURA, FR

Effective date: 20260204

PLFP Fee payment

Year of fee payment: 6